Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
about
Current and emerging treatment strategies for Duchenne muscular dystrophyNutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the ConjectureOnline self-report data for duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefitsPharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophyGene expression profiling identifies molecular pathways associated with collagen VI deficiency and provides novel therapeutic targets.Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.D-Amino Acid Substitution of Peptide-Mediated NF-κB Suppression in mdx Mice Preserves Therapeutic Benefit in Skeletal Muscle, but Causes Kidney Toxicity.Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target.Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients.Fatigue in muscular dystrophies.Muscle-Derived Proteins as Serum Biomarkers for Monitoring Disease Progression in Three Forms of Muscular Dystrophy.Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years' experience in a South Indian teaching hospital.Glucocorticoids Improve Myogenic Differentiation In Vitro by Suppressing the Synthesis of Versican, a Transitional Matrix Protein Overexpressed in Dystrophic Skeletal Muscles.
P2860
Q26741535-225BF3A0-F5AF-46B5-BE0A-1A4BEE006218Q28072269-2B75F146-A3D8-435B-9E94-3D7A2B71E117Q28544012-FECC3E1D-ACF2-4F72-8041-007FC887FA93Q33809437-E889DA61-8F0C-44A9-BC7E-70B500801F16Q33856905-26313A00-2ED5-4AE5-8933-478620DA142DQ35040061-AD907A06-7763-4BCA-9843-1962C541BBDAQ35388411-DA9FAF87-D31D-4AEE-ABF6-D125ADC630AFQ36025707-567DDCD6-845B-4EAD-BE08-08F42F0A1B9CQ36171304-614DA9CF-DA1D-450A-A739-7BDBE8F6A42AQ36334428-63BE0804-4C1E-498E-B4DB-2220F0FFD531Q38062690-42DCA7AD-94A5-4BC4-991A-F953D95F0939Q38302852-BD34F450-DBE8-41E2-9B12-8F4B104FBB5BQ41052606-516C67DA-8FDF-4456-80B5-5A37FF9E7F0AQ47324398-088EB095-2BFF-4405-BB13-90CA770DA289
P2860
Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
@ast
Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
@en
Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
@nl
type
label
Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
@ast
Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
@en
Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
@nl
prefLabel
Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
@ast
Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
@en
Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
@nl
P2860
P3181
P1433
P1476
Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy
@en
P2093
Enrico Peterle
P2860
P3181
P407
P5008
P577
2012-05-01T00:00:00Z